Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia

(RTTNews) - Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia. The safety profile was consistent with that reported in previous studies. The company will present detailed results of the LUNA 3 phase 3 study at a medical congress later in the current year.

Rilzabrutinib was granted Fast Track Designation by the FDA for the treatment of ITP in November 2020 and was previously granted Orphan Drug Designation.

For More Such Health News, visit

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.